摘要
新型冠状病毒感染治疗药物奈玛特韦片/利托那韦片(简称奈/利片)在我国应用日益广泛,但其药物相互作用复杂。尽管说明书、国内外指南提供了奈/利片与心血管药物合用处置建议,但直接用于指导我国临床实践仍有一定局限性,包括国内外药品品种不完全一致、部分推荐意见无法实施等。为此,北京药学会和首都医科大学附属北京安贞医院联合发起,组织医学和药学专家,在系统整理相关资料的基础上,充分考虑我国药品品种情况,结合临床实践经验制定《奈玛特韦片/利托那韦片与心血管药物相互作用实用药学建议》,涉及奈/利片与临床常用心血管药物间相互作用机制、相互作用结果、相互作用级别和实用药学建议,旨在为我国临床实践提供参考。
Nirmatrelvir/ritonavir tablets are widespread used in China, which is a novel therapeutic drug for coronavirus in?fection. Nevertheless, it has complicated interactions with other drugs. Although the instructions and guidelines at home and abroad provide recommendations for the co-administration of nirmatrelvir/ritonavir tablets with cardiovascular drugs, there are still limitations for guiding clinical practice in China, including the inconsistency of drug varieties at home and abroad, and the in?ability to implement some recommendations. Therefore, the Beijing Pharmaceutical Association and Beijing Anzhen Hospital, Capital Medical University organized medical and pharmacy experts to develop “practical pharmacological advice on the drugdrug interactions of nirmatrelvir/ritonavir tablets with cardiovascular drugs” based on relevant information, the situation of drugs, and the clinical practice experience in China. It contains the interaction mechanism, interaction results, and interaction levels, as well as the practical pharmacological recommendations between nirmatrelvir/ritonavir tablets and commonly used cardiovascular drugs in clinical practice, with the aim of providing references for clinical practice in China.
出处
《临床药物治疗杂志》
2023年第1期1-9,共9页
Clinical Medication Journal
